Literature DB >> 10708310

Rhodium-105 tetrathioether complexes: radiochemistry and initial biological evaluation.

N Goswami1, C Higginbotham, W Volkert, R Alberto, W Nef, S Jurisson.   

Abstract

105Rhodium(III) complexes with three different acyclic tetrathioether ligands containing pendant carboxylic acid groups have been synthesized and characterized. The complexes were evaluated for stability under physiological conditions and the most promising complexes were evaluated in vivo in normal mice. The primary route of clearance for these complexes was the renal/urinary system, consistent with the presence of pendant carboxylate groups. The results indicate that the cis-[Rh(III)Cl2(2,5,8,11-tetrathiadodecane-1,12-dicarboxylic acid)]+ complex shows the most promising in vivo characteristics on which to base a potential therapeutic radiopharmaceutical.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10708310     DOI: 10.1016/s0969-8051(99)00070-0

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  4 in total

1.  Stability and in vivo behavior of Rh[16aneS4-diol]211 at complex: a potential precursor for astatine radiopharmaceuticals.

Authors:  Marek Pruszyński; Monika Łyczko; Aleksander Bilewicz; Michael R Zalutsky
Journal:  Nucl Med Biol       Date:  2014-12-23       Impact factor: 2.408

2.  Inorganic chemistry in nuclear imaging and radiotherapy: current and future directions.

Authors:  Valerie Carroll; Dustin W Demoin; Timothy J Hoffman; Silvia S Jurisson
Journal:  Radiochim Acta       Date:  2012-08       Impact factor: 1.440

3.  Preparation of Rh[16aneS4-diol](211)At and Ir[16aneS4-diol](211)At complexes as potential precursors for astatine radiopharmaceuticals. Part I: Synthesis.

Authors:  Marek Pruszyński; Aleksander Bilewicz; Michael R Zalutsky
Journal:  Bioconjug Chem       Date:  2008-03-14       Impact factor: 4.774

Review 4.  A nuclear chocolate box: the periodic table of nuclear medicine.

Authors:  Philip J Blower
Journal:  Dalton Trans       Date:  2015-03-21       Impact factor: 4.390

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.